Style | Citing Format |
---|---|
MLA | Aghsaeifard Z, Alizadeh R. "Clinical Post-Transplant Lymphoproliferative Disorders." Cardiovascular and Hematological Disorders - Drug Targets, vol. 22, no. 2, 2022, pp. 96-103. |
APA | Aghsaeifard Z, Alizadeh R (2022). Clinical Post-Transplant Lymphoproliferative Disorders. Cardiovascular and Hematological Disorders - Drug Targets, 22(2), 96-103. |
Chicago | Aghsaeifard Z, Alizadeh R. "Clinical Post-Transplant Lymphoproliferative Disorders." Cardiovascular and Hematological Disorders - Drug Targets 22, no. 2 (2022): 96-103. |
Harvard | Aghsaeifard Z, Alizadeh R (2022) 'Clinical Post-Transplant Lymphoproliferative Disorders', Cardiovascular and Hematological Disorders - Drug Targets, 22(2), pp. 96-103. |
Vancouver | Aghsaeifard Z, Alizadeh R. Clinical Post-Transplant Lymphoproliferative Disorders. Cardiovascular and Hematological Disorders - Drug Targets. 2022;22(2):96-103. |
BibTex | @article{ author = {Aghsaeifard Z and Alizadeh R}, title = {Clinical Post-Transplant Lymphoproliferative Disorders}, journal = {Cardiovascular and Hematological Disorders - Drug Targets}, volume = {22}, number = {2}, pages = {96-103}, year = {2022} } |
RIS | TY - JOUR AU - Aghsaeifard Z AU - Alizadeh R TI - Clinical Post-Transplant Lymphoproliferative Disorders JO - Cardiovascular and Hematological Disorders - Drug Targets VL - 22 IS - 2 SP - 96 EP - 103 PY - 2022 ER - |